Antioxidant, B vitamin combo to slow dementia?

- Last updated on GMT

Related tags: Vitamin, Folic acid, Alzheimer's disease

Combining B vitamins with a powerful antioxidant could lower blood
levels of the amino acid homocysteine enough to prevent dementia,
claims a UK research firm preparing to test the theory in clinical

High blood levels of homocysteine are a known risk factor for stroke and dementia but although homocysteine can be lowered by standard B vitamin supplements it is not yet known whether these can be used to treat or prevent dementia.

So far, the small studies on this effect have been disappointing.

However homocysteine research company Cobalz​ says that clinical trials starting in January could confirm that adding B vitamins to the powerful antioxidant N-acetylcysteine is superior to standard B vitamins in slowing the rate of cognitive decline in Alzheimer's disease patients.

Dementia already affects millions around the world and the threat is increasing with the growing numbers of elderly. Alzheimer's disease, the leading cause of dementia in the elderly, afflicts an estimated 4.5 million people in the US alone.

The condition is not only associated with homocysteine levels but also with 'free radicals' that oxidise and damage an enzyme that breaks down homocysteine.

Cobalz has found that adding a powerful antioxidant to B vitamins lowers homocysteine levels even further and results in prompt, striking and sustained clinical improvement in patients.

Cobalz claims that the glutathione precursor N-acetylcysteine (NAC)is not only a potent antioxidant but also a source of cysteine. Cysteine is required to generate hydrogen sulphide - an important neuromodulator and vasorelaxant. Levels of hydrogen sulphide levels are severely decreased in the brains of Alzheimer's disease patients.

Last week the firm signed a licensing agreement with US pharmaceutical firm Pamlab to produce the product scheduled for use in the trial by researchers at the University of Texas Southwestern Medical Center.

Neil McCaddon, global head of licensing and corporate development at Cobalz, said: "We are very excited about the possibilities, and hope to announce some real breakthroughs for sufferers of dementia, and their carers."

The UK company is seeking other licensing and development partners for the rest of the global market.

Related topics: Research, Suppliers, Cognitive function

Related news

Show more

Related products

show more

Cognitive Support across Life Stages

Cognitive Support across Life Stages

Kerry | 16-Nov-2022 | Infographic

Proactive adults of all ages see the value of cognitive support, whether for themselves or for more vulnerable family members such as aging parents. 60%...

Improve DOMS and Postexercise Lactate Accumulation

Improve DOMS and Postexercise Lactate Accumulation

Gencor-Pacific | 08-Sep-2022 | Clinical Study

Hydrocurc®’s clinical study suggests that a highly bioavailable curcumin may facilitate a quicker return to exercise training and/or allow a higher training...

DurOmega® Algal DHA 20% water dispersible powder

DurOmega® Algal DHA 20% water dispersible powder

INNOBIO Corporation Limited | 30-May-2022 | Technical / White Paper

INNOBIO most recently launched a new product DurOmega® Algal DHA 20% water dispersible powder with significantly reduced fishy odor and taste, which optimizes...

Related suppliers

Follow us


View more